ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GHDX Stock Price » GHDX Stock News

Genomic Health Share News

 Genomic Health (mm) Stock Price
GHDX Stock Price
 Genomic Health (mm) Stock Chart
GHDX Stock Chart
 Genomic Health (mm) Stock News
GHDX Stock News
 Genomic Health (mm) Company Information
GHDX Company Information
 Genomic Health (mm) Stock Trades
GHDX Stock Trades

FDA Officials Not Sure Agency Will Approve Direct-To-Consumer Genetic Tests

By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- Top Food and Drug Administration officials suggested they would set a high, if not impossible, bar for companies seeking to sell genetic tests directly to consumers. In an interview, Jeffrey Shuren, head of FDA's medical-devices division, and Alberto Gutierrez, who oversees the FDA unit that regulates certain laboratory tests, said they considered direct-to-consumer genetic tests "high risk" and have already informed companies selling such tests through their websites that they must seek FDA approval. Although the FDA hasn't ordered existing tests off the market, Shuren suggested it could be difficult to gain agency approval. The agency is convening a two-day public hearing starting Monday to discuss how it would regulate diagnostic tests, including direct-to-consumer tests. Shuren said he was concerned about cutting doctors out of the process of interpreting laboratory tests and afraid consumers could make risky medical decisions based on information that suggests they are at risk of developing cancer, diabetes or other diseases or could stop taking a needed medication. The issue came to light in May after Pathway Genomics Corp., a closely held firm based in San Diego, announced plans to sell its Insight Saliva Collection Kit through Walgreen Co. (WAG) and CVS Caremark Corp (CVS). Both retailers backed out of plans to sell the test after the FDA raised concerns. The Insight Saliva and similar tests such as ones sold by other California firms, 23andMe Inc. and Navigenics Inc., are designed to predict a person's risk for developing certain diseases or how they might respond to certain drugs. They can also be used to predict the risk of certain diseases caused by recessive genes that might be passed to a child from parents. Shuren noted that the FDA has so far declined to approve an over-the-counter HIV test partly on concerns that test results would be first seen by a consumer and not a doctor. "The question is what's the benefit to consumers," Shuren said. Pathway recently changed course and now requires its test to be ordered through a physician. Traditionally, FDA has regulated laboratory tests that are sold to hospitals and doctor's offices along with over-the-counter tests like blood glucose test strips, but it hasn't required approval for so-called laboratory-developed tests that fall under a system regulated by the Centers for Medicare and Medicaid Services. CMS certifies laboratories, but if a test is analyzed in the same lab, it traditionally hasn't required FDA approval because such tests were considered low-risk and easy to understand. But now that such laboratory-developed tests can predict a person's risk for cancer recurrence or the risk of developing other diseases, FDA officials say those should go through the FDA-approval process. The move will affect several other companies including Quest Diagnostics (DCX) and Laboratory Corporation of America (LH), or LabCor, and Genomic Health Inc. (GHDX), which sells a test that's well regarded in the medical community for predicting the risk of breast-cancer recurrence. The American Clinical Laboratory Association, which represents laboratories, said it believes that current regulations do need to be updated, but said it was concerned that if current FDA medical-device regulations are applied to lab tests that it might impede the development of "cutting edge tests." -By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294;

Stock News for Genomic Health (GHDX)
10/12/201508:00:00Philips teams up with Genomic Health to utilize innovative digital...
10/07/201508:00:00CMS Increases Final Pricing Determination for Oncotype DX® Breast...
10/05/201519:18:11Statement of Changes in Beneficial Ownership (4)
10/05/201517:05:36Statement of Changes in Beneficial Ownership (4)
10/05/201517:03:49Statement of Changes in Beneficial Ownership (4)
10/05/201517:02:57Statement of Changes in Beneficial Ownership (4)
09/28/201508:00:00Genomic Health Responds to Flawed CMS Gap-fill Pricing for Oncotype...
09/28/201507:30:00L'étude TAILORx révèle que 99 % des femmes avec un résultat de...
09/28/201507:30:00TAILORx trial finds 99% of women with low Oncotype DX® Recurrence...
09/28/201501:15:00TAILORx trial finds 99 percent of women with low Oncotype DX®...
09/28/201501:15:00Two Large International Studies Provide Additional Prospective...
09/11/201508:00:00Multiple Oncotype DX® Outcomes Studies, Including Results from...
09/10/201516:40:31Statement of Changes in Beneficial Ownership (4)
08/20/201508:00:00Breast Cancer Research and Treatment Publishes Oncotype DX(R...
08/17/201508:00:00Genomic Health's Oncotype DX® Prostate Cancer Test Receives...
08/06/201517:47:14Quarterly Report (10-q)
08/04/201516:23:38Current Report Filing (8-k)
08/04/201516:07:00Genomic Health Announces Second Quarter 2015 Financial Results...
07/31/201517:57:27Initial Statement of Beneficial Ownership (3)
07/31/201517:56:25Initial Statement of Beneficial Ownership (3)

Genomic Health and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations